ÂÜÀòÂÒÂ×

Mike joined the board of Ossianix in 2013. He is a co-founder and was CSO at Kymab Ltd. (UK). Before joining Kymab, he had several leading positions at GlaxoSmithKline, latterly as SVP and head of Biopharmaceuticals Research. Prior to joining GSK in 2001, he headed the Lymphocyte Molecular Biology group at the Imperial Cancer Research Fund. He has more than 20 years of research experience with a focus on molecular aspects of the immune system. He has more than 150 publications and membership of the European Molecular Biology Organisation and Fellowship of the Academy of Medical Sciences. Mike has been an independent director of Zealand Pharma A/S since 2012 and is also a member of the Board of BLINK Therapeutics (UK). Mike obtained a PhD from Cambridge University where he studied amino acid transport in trypanosomes, and a BA in Biochemistry from Keble College, Oxford University.